(Reuters) – An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in just one of 12 patients with advanced colorectal cancer who were given the highest dose in a small, early-stage trial, the company said on Saturday. The cancer... More »
(Reuters) – The U.S. patent office will review patents on Alexion Pharmaceuticals Inc’s blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday. The move deals a blow to Alexion’s efforts to ward off competition for it... More »
An Amgen sign is seen at the company’s office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo Amgen Inc (AMGN.O) on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp dro... More »
FILE PHOTO – An Amgen sign is seen at the company’s office in South San Francisco, California, U.S. on October 21, 2013. REUTERS/Robert Galbraith/File Photo Amgen Inc’s (AMGN.O) $14,000 cholesterol drug Repatha cut the risk of heart attack and stroke by over 2... More »
An Amgen sign is seen at the company’s office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo Amgen Inc (AMGN.O) sells its cholesterol-lowering drug Repatha at a discount of about 30 percent to its U.S. list price of $1... More »
Data that should help unlock the sales potential of a potent new cholesterol medicine will be unveiled at the American College of Cardiology meeting this week as the future of the only rival drug rests with the courts in an ongoing patent dispute. More »
French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016. REUTERS/Philippe Wojazer/File Photo A U.S. appeals court on Wednesday stayed an order that would have blocked Regeneron Pharmaceuticals Inc and... More »
A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed/File Photo The U.S. Food and Drug Administration has approved Amgen Inc’s treatment for secondary hyperparathyroidism in adult ... More »
An Amgen sign is seen at the company’s office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival ... More »
The U.S. Food and Drug Administration on Friday approved Amgen Inc’s biosimilar version of AbbVie’s top-selling arthritis drug, Humira. More »
